Replies to post #270136 on Amarin Corp Plc (AMRN)

[Triple88]

we need settlement that saves the patents and protects pricing in the US !!!

IF we lose pricing to generics in the US the peak sales in EU will be in jeopardy due to pricing, imo.

EU big 5 will not agree to prices higher than the US which will be at risk IF there are Vascepa Generics in the market.

10.00 for EU conservative [2.5-3B of dollars peak year on sales conservatively speaking expected in Europe with exclusivity for 13 years and you only give 4.1B value to Europe?; Using the 3-5X peaks sale rule I get 7.5-12.5B or 18-30 dollars/share for Europe alone)

[sts66]

*sigh* For the millionth time EU exclusivity is 10 yrs, plus 1 more for a new indication, not 13 yrs or any other number. Nobody can put a value on ROW because nobody knows when V will get the R-IT label in China and what China will pay for V - it may be several more years before they get R-IT indication because Eddingham filed for MARINE indication.